INBRX-106 Phase 1/2 Trial
An Open-Label, Multicenter, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
ClinicalTrials.gov
Key Eligibility Criteria:
F3 Cohort:
+ Locally advanced or metastatic NSCLC
+ <3 prior lines of therapy
+ Checkpoint inhibitor relapsed refractory
+ PD-L1 TPS ≥50% or TMB ≥10 mutations/Mb
F4 Cohort:
+ Recurrent, locally advanced, or metastatic HNSCC (non-NPC) or NPC
+ <1 prior line of chemotherapy in the metastatic setting
+ CPI naïve
+ PD-L1 CPS ≥1
F7 Cohort